



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/747,148	12/19/2000	Roland Buelow	A-61008-1/RFT/TAL	8637

7590

03/20/2002

Todd A. Lorenz, Esq.
FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP
Suite 3400
Four Embarcadero Center
San Francisco, CA 94111-4187

EXAMINER

DECLoux, AMY M

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 03/20/2002

8

Please find below and/or attached an Office communication concerning this application or proceeding.

File A-61008-1 Atty RFT/TAL
Due Date 4/20/2002
Type Sq. Lischy Refs —



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/742,148	12-19-00	Buelow	A-61008-1/RFT/TAL



EXAMINER	
Amy DeCloux	
ART UNIT	PAPER NUMBER
1644	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The reply filed 1/18/02 is not fully responsive to the communication mailed 7-20-01 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures or CRF Diskette Problem Report. This application fails to comply with the requirements of 37 C.F.R. 1.821-1.825 for the reason(s) set forth on the attached Notice. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the above-mentioned reply appears to be *bona fide*, applicant is given a TIME PERIOD of ONE EXTENDABLE MONTH, from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME LIMIT MAY BE GRANTED UNDER 37 CFR 1.136(a).

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS
Submission User Manual - ePAVE)

2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence

**Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202**

**4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy DeCloux whose telephone number is (703) 306-5821. The examiner can normally be reached Monday through Friday from 9:00 am to 6:00 pm. Or a message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Amy DeCloux, Ph.D.
Patent Examiner
Art Unit 1644
March 19, 2002

Amy DeCloux 3-19-02

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:
Applicant Must Provide:
- ☒ ^{*} An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio

(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS
Submission User Manual - ePAVE)

2. Mailed to:

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery
service to:

U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:

2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202



1644

RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY
SYSTEMS
BRANCH



#7
RECEIVED
FEB 12 2002

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/742,148
Source: OIPE
Date Processed by STIC: 1/28/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 09/242,148

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
 (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
 (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 This sequence is intentionally skipped

 Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences
 (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
 <210> sequence id number
 <400> sequence id number
 000
- 9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.
- 10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220> Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
 Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (See 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.



1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/742,148

DATE: 01/28/2002

TIME: 14:15:29

Input Set : A:\A61008-1.txt

Output Set: N:\CRF3\01282002\I742148.raw

pp. 1, 3-6

3 <110> APPLICANT: Buelow, Roland
 5 <120> TITLE OF INVENTION: Cytomodulating Peptide for Inhibiting Lymphocyte Activity
 7 <130> FILE REFERENCE: A-61008-1/RFT/TAL
 9 <140> CURRENT APPLICATION NUMBER: 09/742,148
 10 <141> CURRENT FILING DATE: 2000-12-19
 12 <150> PRIOR APPLICATION NUMBER: 08/433,613
 13 <151> PRIOR FILING DATE: 1995-05-03
 15 <160> NUMBER OF SEQ ID NOS: 57
 17 <170> SOFTWARE: PatentIn version 3.1
 19 <210> SEQ ID NO: 1
 20 <211> LENGTH: 3
 21 <212> TYPE: PRT
 22 <213> ORGANISM: Artificial Sequence
 24 <220> FEATURE:
 25 <223> OTHER INFORMATION: oligopeptide
 27 <400> SEQUENCE: 1
 29 Tyr Tyr Trp
 30 1

33 <210> SEQ ID NO: 2
 34 <211> LENGTH: 4
 35 <212> TYPE: PRT
 36 <213> ORGANISM: Artificial Sequence
 38 <220> FEATURE:
 39 <223> OTHER INFORMATION: oligopeptide
 41 <400> SEQUENCE: 2
 43 Arg Tyr Tyr Trp
 44 1

47 <210> SEQ ID NO: 3
 48 <211> LENGTH: 14
 49 <212> TYPE: PRT
 50 <213> ORGANISM: Artificial Sequence
 52 <220> FEATURE:
 53 <223> OTHER INFORMATION: oligopeptide
 55 <220> FEATURE:
 56 <221> NAME/KEY: MISC_FEATURE
 57 <222> LOCATION: (2)..(2)
 58 <223> OTHER INFORMATION: The amino acid at position 2 can be either Valine or Glutamic

aci

59 d.
 62 <220> FEATURE:
 63 <221> NAME/KEY: MISC_FEATURE
 64 <222> LOCATION: (3)..(3)
 65 <223> OTHER INFORMATION: The amino acid at position 3 can be either Asparagine or

Aspartic

Does Not Comply
 Corrected Diskette Needed

insufficient explanation - give source of
 genetic material
 (see item 1,
 on Enov
 summary
 sheet)

RECEIVED

FEB 12 2002

TECH CENTER 1600/2900

acid.

66

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/742,148

DATE: 01/28/2002
TIME: 14:15:29

Input Set : A:\A61008-1.txt
Output Set: N:\CRF3\01282002\I742148.raw

69 <220> FEATURE:
70 <221> NAME/KEY: MISC_FEATURE
71 <222> LOCATION: (7)..(7)
72 <223> OTHER INFORMATION: The amino acid at position 7 can be either Alanine or
Leucine.
75 <220> FEATURE:
76 <221> NAME/KEY: MISC_FEATURE
77 <222> LOCATION: (9)..(9)
78 <223> OTHER INFORMATION: The amino acid at position 9 can be either Arginine or
Glutamic A
79 cid.
82 <220> FEATURE:
83 <221> NAME/KEY: MISC_FEATURE
84 <222> LOCATION: (13)..(13)
85 <223> OTHER INFORMATION: The amino acid at position 13 can be either Glutamine or
Aspartic
86 acid.
89 <400> SEQUENCE: 3
(9) 91 Arg Xaa Xaa Leu Arg Ile Xaa Leu Xaa Tyr Tyr Trp Xaa Ser
92 1 5 10
95 <210> SEQ ID NO: 4
96 <211> LENGTH: 14
97 <212> TYPE: PRT
98 <213> ORGANISM: Artificial Sequence
100 <220> FEATURE:
101 <223> OTHER INFORMATION: oligopeptide
103 <400> SEQUENCE: 4
105 Ser Gly Ser Gly Arg Val Asn Leu Arg Ile Ala Leu Arg Tyr
106 1 5 10
109 <210> SEQ ID NO: 5
110 <211> LENGTH: 14
111 <212> TYPE: PRT
112 <213> ORGANISM: Artificial Sequence
114 <220> FEATURE:
115 <223> OTHER INFORMATION: oligopeptide
117 <400> SEQUENCE: 5
119 Ser Gly Ser Gly Arg Glu Asn Leu Arg Thr Ala Leu Arg Tyr
120 1 5 10
123 <210> SEQ ID NO: 6
124 <211> LENGTH: 14
125 <212> TYPE: PRT
126 <213> ORGANISM: Artificial Sequence
128 <220> FEATURE:
129 <223> OTHER INFORMATION: oligopeptide
131 <400> SEQUENCE: 6
133 Ser Gly Ser Gly Arg Val Asn Leu Arg Thr Ala Leu Arg Tyr
134 1 5 10
137 <210> SEQ ID NO: 7
138 <211> LENGTH: 14
139 <212> TYPE: PRT
140 <213> ORGANISM: Artificial Sequence
142 <220> FEATURE:

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/742,148

DATE: 01/28/2002
TIME: 14:15:29

Input Set : A:\A61008-1.txt
Output Set: N:\CRF3\01282002\I742148.raw

143 <223> OTHER INFORMATION: oligopeptide
145 <400> SEQUENCE: 7
147 Ser Gly Ser Gly Arg Glu Asp Leu Arg Ile Ala Leu Arg Tyr
148 1 5 10
151 <210> SEQ ID NO: 8
152 <211> LENGTH: 14
153 <212> TYPE: PRT
154 <213> ORGANISM: Artificial Sequence
156 <220> FEATURE:
157 <223> OTHER INFORMATION: oligopeptide
159 <400> SEQUENCE: 8
161 Ser Gly Ser Gly Arg Glu Asx Lys Arg Ile Leu Leu Arg Tyr
162 1 5 10
165 <210> SEQ ID NO: 9
166 <211> LENGTH: 14
167 <212> TYPE: PRT
168 <213> ORGANISM: Artificial Sequence
170 <220> FEATURE:
171 <223> OTHER INFORMATION: oligopeptide
173 <400> SEQUENCE: 9
175 Ser Gly Ser Gly Arg Val Asp Leu Arg Thr Leu Leu Arg Tyr
176 1 5 10
179 <210> SEQ ID NO: 10
180 <211> LENGTH: 14
181 <212> TYPE: PRT
182 <213> ORGANISM: Artificial Sequence
184 <220> FEATURE:
185 <223> OTHER INFORMATION: oligopeptide
187 <400> SEQUENCE: 10
189 Ser Gly Ser Gly Arg Glu Ser Leu Arg Ile Ala Leu Arg Tyr
190 1 5 10
193 <210> SEQ ID NO: 11
194 <211> LENGTH: 14
195 <212> TYPE: PRT
196 <213> ORGANISM: Artificial Sequence
198 <220> FEATURE:
199 <223> OTHER INFORMATION: oligopeptide
201 <400> SEQUENCE: 11
203 Ser Gly Ser Gly Arg Val Ser Leu Arg Thr Ala Leu Arg Tyr
204 1 5 10
207 <210> SEQ ID NO: 12
208 <211> LENGTH: 14
209 <212> TYPE: PRT
210 <213> ORGANISM: Artificial Sequence
212 <220> FEATURE:
213 <223> OTHER INFORMATION: oligopeptide
215 <400> SEQUENCE: 12
217 Ser Gly Ser Gly Arg Glu Asn Ile Arg Asn Ala Leu Arg Tyr
218 1 5 10

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/742,148

DATE: 01/28/2002

TIME: 14:15:29

Input Set : A:\A61008-1.txt

Output Set: N:\CRF3\01282002\I742148.raw

221 <210> SEQ ID NO: 13
222 <211> LENGTH: 14
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial Sequence
226 <220> FEATURE:
227 <223> OTHER INFORMATION: oligopeptide
229 <400> SEQUENCE: 13
231 Ser Gly Ser Gly Arg Glu Asn Leu Arg Ile Ala Arg Arg Tyr
232 1 5 10
235 <210> SEQ ID NO: 14
236 <211> LENGTH: 14
237 <212> TYPE: PRT
238 <213> ORGANISM: Artificial Sequence
240 <220> FEATURE:
241 <223> OTHER INFORMATION: oligopeptide
243 <400> SEQUENCE: 14
245 Ser Gly Ser Gly Arg Glu Asn Leu Arg Ile Ala Leu Gly Tyr
246 1 5 10
249 <210> SEQ ID NO: 15
250 <211> LENGTH: 14
251 <212> TYPE: PRT
252 <213> ORGANISM: Artificial Sequence
254 <220> FEATURE:
255 <223> OTHER INFORMATION: oligopeptide
257 <400> SEQUENCE: 15
259 Ser Gly Ser Gly Arg Glu Ser Leu Arg Asn Leu Arg Gly Tyr
260 1 5 10
263 <210> SEQ ID NO: 16
264 <211> LENGTH: 14
265 <212> TYPE: PRT
266 <213> ORGANISM: Artificial Sequence
268 <220> FEATURE:
269 <223> OTHER INFORMATION: oligopeptide
271 <400> SEQUENCE: 16
273 Ser Gly Ser Gly Glu Asn Leu Arg Ile Ala Leu Arg Tyr Tyr
274 1 5 10
277 <210> SEQ ID NO: 17
278 <211> LENGTH: 14
279 <212> TYPE: PRT
280 <213> ORGANISM: Artificial Sequence
282 <220> FEATURE:
283 <223> OTHER INFORMATION: oligopeptide
285 <400> SEQUENCE: 17
287 Ser Gly Ser Gly Asn Leu Arg Ile Ala Leu Arg Tyr Tyr Trp
288 1 5 10
291 <210> SEQ ID NO: 18
292 <211> LENGTH: 14
293 <212> TYPE: PRT
294 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/742,148

DATE: 01/28/2002
TIME: 14:15:29

Input Set : A:\A61008-1.txt
Output Set: N:\CRF3\01282002\I742148.raw

296 <220> FEATURE:
297 <223> OTHER INFORMATION: oligopeptide
299 <400> SEQUENCE: 18
301 Ser Gly Ser Gly Leu Arg Ile Ala Leu Arg Tyr Tyr Trp Asp
302 1 5 10
305 <210> SEQ ID NO: 19
306 <211> LENGTH: 13
307 <212> TYPE: PRT
308 <213> ORGANISM: Artificial Sequence
310 <220> FEATURE:
311 <223> OTHER INFORMATION: oligopeptide
313 <400> SEQUENCE: 19
315 Ser Gly Ser Gly Ile Ala Leu Arg Tyr Tyr Trp Asp Ser
316 1 5 10
319 <210> SEQ ID NO: 20
320 <211> LENGTH: 13
321 <212> TYPE: PRT
322 <213> ORGANISM: Artificial Sequence
324 <220> FEATURE:
325 <223> OTHER INFORMATION: oligopeptide
327 <400> SEQUENCE: 20
329 Ser Gly Ser Gly Ala Leu Arg Tyr Tyr Trp Asp Ser Glu
330 1 5 10
333 <210> SEQ ID NO: 21
334 <211> LENGTH: 13
335 <212> TYPE: PRT
336 <213> ORGANISM: Artificial Sequence
338 <220> FEATURE:
339 <223> OTHER INFORMATION: oligopeptide
341 <400> SEQUENCE: 21
343 Ser Gly Ser Gly Leu Arg Tyr Tyr Trp Asp Ser Glu Ala
344 1 5 10
347 <210> SEQ ID NO: 22
348 <211> LENGTH: 12
349 <212> TYPE: PRT
350 <213> ORGANISM: Artificial Sequence
352 <220> FEATURE:
353 <223> OTHER INFORMATION: oligopeptide
355 <400> SEQUENCE: 22
357 Ser Gly Ser Gly Arg Ile Ala Leu Arg Ala Ala Ala
358 1 5 10
361 <210> SEQ ID NO: 23
362 <211> LENGTH: 13
363 <212> TYPE: PRT
364 <213> ORGANISM: Artificial Sequence
366 <220> FEATURE:
367 <223> OTHER INFORMATION: oligopeptide →
369 <400> SEQUENCE: 23
371 Ser Gly Ser Gly Arg Ile Ala Leu Arg Ala Ala Ala

The types of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.

Use of n and/or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

FYI

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/742,148

DATE: 01/28/2002

TIME: 14:15:30

Input Set : A:\A61008-1.txt

Output Set: N:\CRF3\01282002\I742148.raw

L:91 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:952 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57
L:956 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:57